Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 5,000 Shares

Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri sold 5,000 shares of Knight Therapeutics stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of C$5.75, for a total value of C$28,750.00.

Amal Khouri also recently made the following trade(s):

• On Thursday, July 11th, Amal Khouri sold 10,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.70, for a total value of C$57,000.00.
• On Wednesday, July 3rd, Amal Khouri sold 10,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.72, for a total transaction of C$57,200.00.
• On Monday, June 10th, Amal Khouri sold 20,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.80, for a total transaction of C$116,022.00.

Knight Therapeutics Stock Down 1.2 %

GUD opened at C$5.67 on Thursday. The company has a market capitalization of C$574.82 million, a P/E ratio of -35.44, a P/E/G ratio of -1,013.50 and a beta of 0.46. The company has a debt-to-equity ratio of 9.20, a current ratio of 3.34 and a quick ratio of 1.79. The firm’s fifty day moving average price is C$5.66 and its two-hundred day moving average price is C$5.64. Knight Therapeutics Inc. has a fifty-two week low of C$4.35 and a fifty-two week high of C$6.22.

Wall Street Analyst Weigh In

GUD has been the subject of a number of research analyst reports. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the company from C$5.75 to C$6.75 in a report on Tuesday.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.